Skip to main content

Table 1 Baseline characteristics of study population of new users and non-users of statins

From: Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

  Exposed (new users) Unexposed
Baseline characteristics n (%) n (%)
All patients (n = 2,016,094) 430,890 (21.37) 1,585,204 (78.63)
Gender   
Male 231,732 (53.78) 835,053 (52.68)
Female 199,158 (46.22) 750,151 (47.32)
Age mean (sd), yrs 63.77 (10.81) 61.86 (11.27)
30-39 7,584 (1.76) 37,221 (2.35)
40-49 37,386 (8.68) 183,876 (11.60)
50-59 100,079 (23.23) 455,649 (28.74)
60-69 146,431 (33.98) 490,132 (30.92)
70-79 109,894 (25.50) 311,974 (19.68)
80-85 29,516 (6.85) 106,352 (6.71)
BMI, kg/m 2   
<20 11,223 (2.60) 65,496 (4.13)
20-25 107,711 (25.00) 457,240 (28.84)
>25 290,876 (67.51) 831,395 (52.45)
Unknown 21,080 (4.89) 231,073 (14.58)
Smoking status   
Current smokers 90,670 (21.04) 266,333 (16.80)
Former smoker 163,576 (37.96) 532,087 (33.57)
Non-smoker/never 175,360 (40.70) 706,908 (44.59)
Unknown status 1,284 (0.30) 79,876 (5.04)
Alcohol use   
Current (unknown amount) 21,009 (4.88) 43,762 (2.76)
Rare drinker (<2u/d) 63,213 (14.67) 229,758 (14.49)
Moderate drinker (3-6u/d) 223,242 (51.81) 757,940 (47.81)
Excessive drinker (>6u/d) 40,912 (9.49) 135,790 (8.57)
Past use 8,130 (1.89) 40,337 (2.54)
Non-drinker 53,566 (12.43) 161,639 (10.20)
Unknown status 20,818 (4.83) 215,978 (13.62)
Family history of:   
Diabetes 17,914 (4.16) 55,962 (3.53)
Cardiovascular disease 113,104 (26.25) 307,406 (19.39)
Diagnosis of:   
Hyperlipidaemia 29,140 (6.76) 30,277 (1.91)
Atherosclerosis 1,664 (0.39) 2,175 (0.14)
Hypertension 176,946 (41.07) 352,371 (22.23)
Heart failure 10,448 (2.42) 20,160 (1.27)
Cardiovascular disease 98,739 (22.92) 101,666 (6.41)
Atrial fibrillation 17,907 (4.16) 36,005 (2.27)
Hepatic disease (within 6 months) 1,808 (0.42) 5,736 (0.36)
Kidney disease (within 6 months) 13,813 (3.21) 27,352 (1.73)
Abnormal glucose level 6,076 (1.41) 11,757 (0.74)
Osteoporosis 13,047 (3.03) 45,262 (2.86)
Cancer 42,929 (9.96) 159,664 (10.07)
Thyroid disease 34,863 (8.09) 105,555 (6.66)
Prior use of:   
Antipsychotics (within 6 months) 252 ( 0.06) 1,317 (0.08)
Antidepressants (within 6 months) 5,876 (1.36) 15,495 (0.98)
Cardiovascular drugs 124,687 (28.94) 608,423 (38.38)
Nonstatin lipid lowerers (within 3 months) 894 (0.21) 336 (0.02)
Systemic glucocorticoids (within 6 months) 5,617 (1.30) 14,354 (0.91)
Oestrogens/HRT (within 1 year) 3,222 (0.75) 6,265 (0.40)
Bisphosphonates (within 1 year) 2,310 (0.54) 10,154 (0.64)
CYP450 3A4 inhibitor 6,962 (1.62) 13,363 (0.84)
Annual consultation rate, mean (SD) 25.99 (18.56) 15.76 (17.42)
Annual prescription rate, mean (SD) 25.80 (31.69) 8.34 (21.02)
  1. All the differences between groups were significant at the 0.05 level (two-sided).